Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors

NCT05795595 is registered in ClinicalTrials.gov with CRISPR Therapeutics AG as lead sponsor.

NCT NCT05795595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05795595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed or Refractory Solid Tumors
Lead sponsor
CRISPR Therapeutics AG
Phase
Phase 1/2
Overall status
Completed
Start date
March 13, 2023
Completion date
September 18, 2025
Enrollment
19 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cervical carcinoma, clear cell renal cell carcinoma, esophageal carcinoma, malignant pleural mesothelioma, pancreatic adenocarcinoma